Palisade Bio (PALI) stock

Market cap $249M

$1.46
+1.39%

Market closed. Prices as of today's close.

Quality Score
-6
Poor
In its industry
#264of 300

PALI's Quality Score was unchanged on Mon, Oct 5, at -7.

Next2H 2026“…2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn’s disease expected in the second half of 2026”Filing with regulators · 8-K, Aug 10
Cash$125M, Over 5 years at the last year's spendingOn Jun 30

Follow PALI's trial news. Pro members can get an alert when Palisade Bio files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when PALI files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Cash$125M, Over 5 years at the last year's spendingOn Jun 30

What's next for PALI, and how long its cash lasts

From Palisade Bio’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

2H 2026“IND for Phase 2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn’s disease expected in the second half of 2026”Filing with regulators · 8-K, Aug 10

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

Lead program
PALI-2108
Another trial
ASCENTRA-UCPhase 2 · Recruiting · 204 people · main data estimated Oct 2027 · NCT07845487

1 more trial, 4 more milestones and 29 filings, for Pro members.

Cash runway Jun 30 balance sheet

Over 5 years

$125M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed May 12, 2026)
  • At-the-market share sales program (S-3, filed May 12, 2026)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Director Robert Baltera Jr. bought 45,000 shares on Jul 9. 8 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

For Pro members: every trade, and John Finley’s 9 filings and quotes.

Get an optional alert when PALI files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 114 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why it's down

Down 29% in 3 months, 25% under its 50-day average.

Down more than its industry: the 299 other stocks in it fell a median 14% over the same 3 months.

−3Long-term trend below a falling 200-day average, down over one year, down over two years

5 more things pulling PALI's score down, for Pro members

What's next

Expected to report Mon Nov 9, after the close

After its last 2 reports it closed -0.3% on average, higher 1 of 2 times.

What would turn PALI's score around: 8 things, for Pro members

Alert me when PALI's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price with the bid and ask.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on PALI and every other stock.

  • FDA dates, counted down

    Each date in the company's own words, its cash against the date, and an optional alert before it.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, download a CSV, and set optional alerts.

  • Congress trades

    Each member's trades. Sort, filter, download a CSV, and set optional alerts.

  • All 14 chart checks

    Trend, volume, tight range, and buying, each lit when it fires, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports. Optional alerts before them.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    AI chips, quantum, nuclear, defense, space, and more, each stock ranked by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push, email, or the bell.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name, with optional alerts.

  • A trade plan, from the chart

    Entry, stop, and two targets on every stock's page. Type your risk and it sizes the trade.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

PALI has 2 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown

Averages stacked in order, price near its high.

Volume1 of 3 shown

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown

The daily range is tight against its own recent history.

Buying1 of 3 shown

Closes near the high, and buyers step in on dips.

The other 10 checks on PALI, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

  • RSI 1435.8

    Above 30, below 50.

  • MACD (12, 26, 9)Below signal

    Crossed below its signal line 17 sessions ago.

  • The price is 23.6% below it.

  • The price is 23.6% below it. The 50-day is below the 200-day, since Oct 5.

  • ADX 1435.4

    25 or more, with +DI below -DI.

  • Support$1.45

    Swing low from Jan 30, 0.7% below the price.

  • Swing high from Feb 10, 26.0% above the price.

  • The bands run from $1.18 to $2.22.

  • Volume0.4x

    Against its 20-day average, for the time of day.

How PALI ranks in Biotech

PALI is #264 of 300 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

When does PALI report earnings, and what happens after?

Expected to report Mon Nov 9, after the close (in 35 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Aug 10, 2026After close-2.4%+1.9%+2.4%
May 12, 2026After close0.0%-2.6%-5.7%

The gap is the next open against the close before the report; the reaction is where that session closed. PALI closed higher after 1 of its last 2. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

Who is trading PALI

PALI insider trades

2 insiders bought $279K across 8 filings, and 2 insiders sold $410K across 2 filings, in the last 6 months. The newest:

BuyDonald Allen Williams$15KDirectorat $1.46 on Oct 2, filed today
All 10 insider filings on PALI from the last six months, for Pro members.Get in free →

An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.

About Palisade Bio

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

14 employeesCarlsbad, CApalisadebio.com

Pro members see every line of every stock's score.

  • Real-⁠time prices, no delay
  • Every line of PALI's score, with the points and the reason
  • All 14 checks on PALI and on all 3,243 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on PALI
BreakawaynowDonald Allen Williams bought PALI$15K at $1.46, filed Oct 5

What a filing on PALI would have sent. Alerts are optional.

See all 14 checks on PALISee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.